Ecron Acunova (EA), a CRO with presence in Europe and Asia, announced a joint venture with Jamjuree Innovations Co. Ltd., (JJI) Thailand. JJI is a 100% subsidiary of Chulalongkorn University Intellectual Property Foundation and enjoys strong ties with the University’s Faculty of Medicine, including Clinical Research Center (Chula CRC). The joint venture CRO is based in Bangkok and will conduct clinical research in key South East Asian countries under the name Ecron Acunova Company Ltd (EACL). Dr. Eugene Kroon MD is appointed CEO of EACL.
EA brings over two decades of clinical research experience in Ph I-IV trials, PK/PD services, clinical trial laboratory, and clinical data management on a global scale. EA has centers in oncology at Berlin, in diagnostic imaging agents in Frankfurt, and in stem cell therapy and diabetes at Bangalore. Chula CRC brings experience in PK/PD, clinical trial laboratory, data management, and HIV research in Thailand and SEA region.
Speaking on the joint venture, Dr. Kiat Ruxrungtham, Professor of Medicine, Chulalongkorn University and Chairman of EACL said, “We look forward to further expanding our model of hands-on local study and investigator relationship management in Southeast Asia for our clients through the joint venture with EA.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.